Assembly Biosciences (ASMB) – Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Assembly Biosciences (NASDAQ: ASMB) in the last few weeks:

  • 6/25/2019 – Assembly Biosciences was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly’s product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. “
  • 6/24/2019 – Assembly Biosciences was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 6/24/2019 – Assembly Biosciences was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $15.00 price target on the stock. According to Zacks, “Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly’s product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. “
  • 6/11/2019 – Assembly Biosciences was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 5/22/2019 – Assembly Biosciences was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 5/14/2019 – Assembly Biosciences was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 5/10/2019 – Assembly Biosciences had its “outperform” rating reaffirmed by analysts at William Blair.

Shares of ASMB stock opened at $13.86 on Wednesday. Assembly Biosciences Inc has a 12-month low of $12.75 and a 12-month high of $44.65. The company has a market cap of $329.59 million, a P/E ratio of -3.48 and a beta of 1.61. The company’s 50-day moving average price is $15.00. The company has a quick ratio of 7.97, a current ratio of 7.97 and a debt-to-equity ratio of 0.06.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.01. The firm had revenue of $3.89 million during the quarter, compared to the consensus estimate of $3.81 million. Assembly Biosciences had a negative net margin of 671.48% and a negative return on equity of 56.45%. As a group, equities research analysts predict that Assembly Biosciences Inc will post -4.34 earnings per share for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. boosted its stake in Assembly Biosciences by 3.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 82,769 shares of the biopharmaceutical company’s stock worth $3,074,000 after purchasing an additional 3,022 shares during the period. Morgan Stanley increased its position in shares of Assembly Biosciences by 13.8% during the third quarter. Morgan Stanley now owns 76,824 shares of the biopharmaceutical company’s stock valued at $2,854,000 after buying an additional 9,310 shares during the period. Rhumbline Advisers increased its position in shares of Assembly Biosciences by 52.9% during the fourth quarter. Rhumbline Advisers now owns 27,744 shares of the biopharmaceutical company’s stock valued at $628,000 after buying an additional 9,602 shares during the period. New York State Common Retirement Fund increased its position in shares of Assembly Biosciences by 15.3% during the fourth quarter. New York State Common Retirement Fund now owns 23,300 shares of the biopharmaceutical company’s stock valued at $527,000 after buying an additional 3,100 shares during the period. Finally, BlackRock Inc. increased its position in shares of Assembly Biosciences by 3.4% during the fourth quarter. BlackRock Inc. now owns 1,909,510 shares of the biopharmaceutical company’s stock valued at $43,193,000 after buying an additional 63,554 shares during the period. Hedge funds and other institutional investors own 86.44% of the company’s stock.

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Featured Story: Net Margin

Receive News & Ratings for Assembly Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.